Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

A Comparative Study of Intravenous Versus Peribulbar Administration of Dexmedetomidine for Strabismus Surgery in Adults

ID
Name
520/3/21
Description
Using various adjuvants has become a trend in regional anesthesia practice to improve the quality of anesthesia and prolong postoperative analgesia. Dexmedetomidine, an alpha-2 agonist has been proposed as a safe and effective adjunct capable of extending the duration of the single-shot block
Trial arms
Trial start
2022-01-28
Estimated PCD
2023-07-01
Trial end
2023-09-15
Status
Completed
Treatment
Dexmedetomidine
to compare perineural (peribulbar) dexmedetomidine versus intravenous (I.V.) dexmedetomidine when used as an adjuvant with local anesthesia in adult strabismus surgery.
Arms:
Intravenous dexmedetomidine, Peribulbar dexmedetomidine
Other names:
alpha-2 agonist
Size
46
Primary endpoint
duration of analgesia
12 hours
Eligibility criteria
Inclusion Criteria: 1. The patient planned to perform a unilateral strabismus surgery 2. Age: 20-60 years 3. American Society of Anesthesiologists class I and II Exclusion Criteria: 1. patients under the age of 20 2. uncooperative patients 3. Patients with coagulopathy 4. patients who disincline to participate in the study will be excluded from the study
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 46, 'type': 'ACTUAL'}}
Updated at
2023-11-15

1 organization

1 product

1 indication

Organization
Aswan University Hospital
Product
Dexmedetomidine
Indication
Strabismus